- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03808558
Phase 2 Study of TVB-2640 in KRAS Non-Small Cell Lung Carcinomas
A Phase 2 Multi-center Pharmacodynamics Study of TVB-2640 in KRAS Mutant Non-small Cell Lung Carcinomas
Study Overview
Detailed Description
Patients with stable disease or partial/complete remissions will continue therapy.
The endpoints are response rate-RR, disease control rate-DCR, PFS-progression-free survival, CTCAEv5.0 toxicities, plasma lipid levels, collection of sebaceous secretion via Sebutape, and 11C-acetate PET tumor imaging.
In the first stage, 13 patients will be enrolled. If fewer than 2 patients achieve response, the study will be stopped. If 2 or more patients have a radiographic response, an additional 21 patients will be enrolled , for a total accrual of 34 patients.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: David Gerber, MD
- Email: david.gerber@utsouthwestern.edu
Study Contact Backup
- Name: Ebele Mbanugo, PhD
- Phone Number: 214-648-7097
- Email: Ebele.mbanugo@UTSouthwestern.edu
Study Locations
-
-
Ohio
-
Cincinnati, Ohio, United States, 45267
- Recruiting
- University of Cincinnati
-
Contact:
- UCCC Clinical Trials Office
- Phone Number: 513-584-7698
- Email: cancer@uchealth.com
-
-
Texas
-
Dallas, Texas, United States, 75390-9179
- Recruiting
- University of Texas Southwestern Medical Center
-
Principal Investigator:
- David Gerber, MD
-
Contact:
- David Gerber, MD
- Phone Number: 214-648-4180
- Email: David.Gerber@utsouthwestern.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion:
Metastatic or advanced stage, histologically or cytologically confirmed NSCLC and molecular identification of oncogenic KRAS mutation.
- KRAS mutant NSCLC must be refractory, relapsed, and previously treated with doublet chemotherapy and immune checkpoint inhibitor (unless there is a specific contraindication to checkpoint inhibitor).
- Molecular characterization (tissue- or blood-based [ie, cell-free/circulating tumor DNA]) must have been performed and must have demonstrated an oncogenic KRAS mutation (e.g., exon 12, 13, 61, or 117 mutation detected by sequencing) by a CLIA-certified assay (source documentation required). KRAS mutations at other codons require review and approval by Study Chair.
- Subjects' EGFR mutation and ALK gene rearrangement status must be known prior to study entry. Subjects with EGFR mutation or ALK gene rearrangement must have progressed after appropriate FDA-approved targeted therapy options prior to eligibility.
- Patient has evidence of disease progression on most recent line of therapy.
- Patient has measurable disease by RECIST v1.1 (Eisenhauer, 2009).
- Age ≥ 18 years.
- ECOG performance status of 0 or 1.
- Predicted life expectancy of >3 months.
Adequate organ and marrow function as defined below:
- absolute neutrophil count ≥ 1,500/mcL
- platelets ≥ 75,000/mcL
- total bilirubin <2X institutional upper limit of normal
- AST and ALT ≤5X institutional upper limit of normal
- serum creatinine <1.5X institutional upper limit of normal
- LVEF >50%
- QTcF <470msec
Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 90 days following completion of therapy. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.
A female of child-bearing potential is any woman (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria:
- Has not undergone a hysterectomy or bilateral oophorectomy; or
- Has not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months).
- No significant ischemic heart disease or myocardial infarction within 6 months of first dose of TVB-2640 and with current adequate cardiac function as in 3.1.8.
- Ability to understand and the willingness to sign a written informed consent.
Exclusion:
- Patient is unable to swallow oral medications or has impairment of GI function or GI disease that may significantly alter drug absorption such as active inflammatory bowel disease, uncontrolled nausea, vomiting, diarrhea, or malabsorption syndrome.
- Patient has a history of risk factors for torsade de pointes such as uncontrolled heart failure, severe hypokalemia with potassium less than 3mM/L, history of long QT syndrome or require use during study participation of concomitant medications known to prolong QT/QTc interval.
- Patients who require use of strong CYP3A4/5 agonists or inhibitors during study participation.
- Patient has uncontrolled or severe intercurrent medical condition including uncontrolled brain metastases. Patients with stable brain metastases either treated or untreated, on a stable dose of steroids/anticonvulsants, with no dose increase within 4 weeks before the first dose of TVB-2640, and no anticipated dose change, are allowed.
- Patient underwent major surgery within 4 weeks before the first dose of TVB-2640 or received cancer-directed therapy either chemotherapy, radiotherapy, hormonal therapy, biologic or immunotherapy, etc. or an investigational drug or device within 2 weeks (6 weeks for mitomycin C and nitrosoureas) or 5 half-lives of that agent, whichever is shorter before the first dose of TVB-2640. In addition, any drug- related toxicity, with the exception of alopecia, an endocrinopathy controlled with replacement therapy, or a clinically stable toxicity not expected to increase from study therapy (eg, cisplatin-associated ototoxicity) should have recovered to <Grade 1.
- If female, patient is pregnant or breast-feeding.
- Patient has evidence of a serious active infection-infection requiring treatment with intravenous antibiotics.
- Patient has known immunodeficiency virus-HIV or hepatitis B or C infection, as such patients may be at increased risk for toxicity due to concomitant treatment and disease-related symptoms may preclude accurate assessment of the safety of TVB-2640.
- Patient has an important medical illness or abnormal laboratory finding that, in the Investigator's opinion, would increase the risk of participating in this study.
- Patients with prior or concurrent malignancy whose natural history or treatment has the potential to interfere with the safety or efficacy assessment of the investigational agent.
- History of clinically significant dry eye (xerophthalmia) or other corneal abnormality or, if a contact lens wearer, does not agree to abstain from contact lens use from baseline through the last study drug dose.
- Patient has a known allergy or hypersensitivity to components of TVB-2640.
- Patient has a prior history of hypersensitivity, drug/radiation-induced, or other immune-mediated pneumonitis.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: TVB-2640
Patients will be administered TVB-2640 100mg/m2 orally once a day for 8 weeks.
|
TVB-2640 will be administered 100mg/m2 orally once a day for 8 weeks.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Disease control rate of TVB-2640
Time Frame: every 8 weeks through study completion, an average of 1 year
|
Determine Disease control rate of TVB-2640 in KRAS mutant NSCLC patients through RECIST and toxicity profile.
|
every 8 weeks through study completion, an average of 1 year
|
Response rate of TVB-2640
Time Frame: every 8 weeks through study completion, an average of 1 year
|
Determine response rate of TVB-2640 in KRAS mutant NSCLC patients through RECIST and toxicity profile.
|
every 8 weeks through study completion, an average of 1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety profile of TVB-2640
Time Frame: Pretreatment and four weeks of treatment.
|
Secondary endpoints are 11C-acetate tumor uptake pretreatment and at four weeks of treatment and plasma lipidomics pretreatment and at four weeks of treatment.
|
Pretreatment and four weeks of treatment.
|
Establish the predictive value of 11C-acetate PET
Time Frame: Pretreatment and four weeks of treatment.
|
To establish the predictive value of 11C-acetate PET pretreatment and post-treatment tumor uptake for disease control rate and response rate
|
Pretreatment and four weeks of treatment.
|
Mean change in fasting plasma lipidomics
Time Frame: Pretreatment and four weeks of treatment.
|
Blood samples for fasting plasma lipidomics will be collected at baseline and four weeks of treatment.
|
Pretreatment and four weeks of treatment.
|
Mean change in sebaceous secretion of fatty acids
Time Frame: Pretreatment and four weeks of treatment.
|
Sebutabe collection of sebaceous secretion of fatty acids will be performed at baseline and four weeks of treatment
|
Pretreatment and four weeks of treatment.
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: David Gerber, MD, Professor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- STU 022017-058
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on KRAS Gene Mutation
-
Calithera Biosciences, IncCompletedNSCLC | Solid Tumors | KRAS Gene Mutation | CRCUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingAdvanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | KRAS Gene Mutation | Metastatic Malignant Solid Neoplasm | EGFR Gene Mutation | ERBB2 Gene Amplification | ERBB2 Gene Mutation | EGFR Gene Amplification | ERBB3 Gene Mutation | ERBB4 Gene MutationUnited States
-
University of VirginiaActive, not recruitingReal-Time Monitoring of Symptoms in Lung Cancer Patients Receiving Oral Targeted Therapies (Lung001)Lung Cancer | ALK Gene Mutation | MET Gene Mutation | KRAS Mutation-Related Tumors | RET Gene Mutation | EGFR Gene Mutation | EGFR | ROS1 Gene Mutation | BRAFUnited States
-
Nested Therapeutics, IncRecruitingGlioma | Melanoma | NSCLC | Oncology | Solid Tumor, Adult | MEK Mutation | RAF Gene Mutation | Ras (KRAS or NRAS) Gene Mutation | MAPK Pathway Gene MutationAustralia
-
University Health Network, TorontoBayer; AstraZeneca; Amgen; Applied Health Research Centre; Takeda Canada, Inc.; Programs...RecruitingCancer | Malignancies Multiple | Malignant Solid Tumor | Cancer, Therapy-Related | Molecular Sequence Variation | Genetic Alteration | Gene Fusion | Receptor Tyrosine Kinase Gene Mutation | RTK Family Gene Mutation | Ras (Kras or Nras) Gene MutationCanada
-
Dr Cipto Mangunkusumo General HospitalCompletedColorectal Cancer | APC Gene Mutation | TP53 Gene Mutation | PIK3CA Gene Mutation | KRAS Mutation-Related Tumors | MLH1 Gene MutationIndonesia
-
Hospital Erasto GaertnerAstraZenecaCompletedLung Neoplasms | KRAS Gene Mutation | EGFR Gene MutationBrazil
-
Intergroupe Francophone de Cancerologie ThoraciqueCompletedCarcinoma, Non-Small-Cell Lung | KRAS Gene Mutation | ALK Gene Mutation | BRAF Gene MutationFrance
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI); Eli Lilly and Company; Genentech, Inc.; Kazia... and other collaboratorsRecruitingMetastatic Malignant Solid Neoplasm | Metastatic Malignant Neoplasm in the Brain | NTRK Family Gene Mutation | CDK Gene Mutation | PI3K Gene Mutation | ROS1 Gene Mutation | KRAS G12C MutationUnited States
-
Karen-Lise Garm SpindlerCompletedColorectal Cancer Metastatic | KRAS Gene Mutation | Circulating Tumor DNA | BRAF Gene Mutation | NRAS Gene Mutation | Epidermal Growth Factor Receptor InhibitorDenmark
Clinical Trials on TVB-2640
-
Ascletis Pharmaceuticals Co., Ltd.Completed
-
Sagimet Biosciences Inc.CompletedSolid Malignant TumorUnited Kingdom, United States
-
Weill Medical College of Cornell UniversitySagimet Biosciences Inc.RecruitingProstatic Neoplasms, Castration-ResistantUnited States
-
Sagimet Biosciences Inc.Active, not recruitingHealthy VolunteersUnited States
-
Sagimet Biosciences Inc.CompletedCirrhosis | Hepatic Impairment | Non-alcoholic SteatohepatitisUnited States, Hungary
-
Sagimet Biosciences Inc.CompletedNonalcoholic Fatty Liver DiseaseUnited States, Canada, Puerto Rico, Poland
-
Sagimet Biosciences Inc.CompletedNon-Alcoholic Fatty Liver DiseaseChina, United States
-
Mark EversNational Cancer Institute (NCI)RecruitingColon CancerUnited States
-
The University of Texas Health Science Center at...CompletedAstrocytomaUnited States
-
Ascletis Pharmaceuticals Co., Ltd.RecruitingRecurrent GlioblastomaChina